Astrazeneca (AZN) Accumulated Expenses (2019 - 2021)

Astrazeneca has reported Accumulated Expenses for 3 years, with the latest figure at -$911.0 million in Q1 2021.

• On a quarterly basis, Accumulated Expenses changed N/A year-over-year to -$911.0 million in Q1 2021; TTM through Mar 2021 was -$911.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at $1.1 billion, up 1115.08% from the prior year.
• Accumulated Expenses was -$911.0 million for Q1 2021 at Astrazeneca, down from $1.1 billion in the prior quarter.
• The five-year high for Accumulated Expenses was $1.1 billion in Q4 2020, with the low at -$911.0 million in Q1 2021.
• Average Accumulated Expenses over 3 years is $87.7 million, with a median of $89.3 million recorded in 2019.
• The largest YoY upside for Accumulated Expenses was 1115.08% in 2020 against a maximum downside of 1115.08% in 2020.
• Over 3 years, Accumulated Expenses stood at $89.3 million in 2019, then surged by 1115.08% to $1.1 billion in 2020, then slumped by 183.99% to -$911.0 million in 2021.
• The last three Accumulated Expenses figures came in at -$911.0 million (Q1 2021), $1.1 billion (Q4 2020), and $89.3 million (Q4 2019), per Business Quant data.